TELA Bio, Inc. (TELA) Earnings
TELA Bio, Inc. is expected to report next earnings on November 12, 2026 (in NaN days), with a consensus EPS estimate of $-0.19. TELA has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -16.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.17 | $-0.20 | -15.1% | $19M | -3.6% |
| May 12, 2026 | $-0.14 | $-0.21 | -50.0% | $19M | +2.5% |
| Mar 24, 2026 | $-0.18 | $-0.16 | +11.1% | $21M | -0.8% |
| Nov 13, 2025 | $-0.17 | $-0.19 | -11.8% | $21M | -1.7% |
| May 8, 2025 | $-0.21 | $-0.25 | -19.0% | $19M | +6.7% |
| Mar 20, 2025 | $-0.24 | $-0.23 | +4.2% | $18M | -16.1% |
| Nov 7, 2024 | $-0.37 | $-0.42 | -13.5% | $19M | -18.2% |
| May 9, 2024 | $-0.48 | $-0.23 | +52.1% | $17M | +1.7% |
| Mar 21, 2024 | $-0.44 | $-0.53 | -20.5% | $17M | +3.7% |
| Nov 9, 2023 | $-0.52 | $-0.45 | +13.5% | $15M | -8.2% |
| May 11, 2023 | $-0.51 | $-0.63 | -23.5% | $12M | -0.9% |
| Mar 21, 2023 | $-0.58 | $-0.52 | +10.3% | $12M | -11.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 10, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Leadership Transition * Heather Goetz was appointed as new Chief Executive Officer and Director of TeleBio, with a proven track record of operational excellence and business transformation; former founder and CEO Tony Koblish stepped down after leading the company through early-stage growth, and the board thanked him for his contributions building the company's core product portfolio. * Goetz emphasized the strong potential of TeleBio's differentiated product portfolio, which serves the large 2.8 billion U.S. soft tissue reconstruction market, with robust clinical data demonstrating industry-leading outcomes for Ovitex (a 2.6% hernia recurrence rate, one of the lowest in the industry). - Commercial Operational Updates * Q2 2026 total revenue came in at $19.3 million, a 4% YoY decline and below management expectations, with the shortfall almost entirely concentrated in the Ovitex PRS segment. * A dedicated PRS sales representative pilot program launched in January 2026 created unintended confusion across the broader sales organization, leading to revenue declines; management stopped the pilot and returned to the original full-portfolio territory structure, and is rolling out a comprehensive new training program for all U.S. field sales representatives focused on PRS engagement. * New sales representative ramp to full productivity is taking longer than the original 6-month target, now expected to take 9-12 months due to market competition and the need for extensive product onboarding and training; management has added additional in-house and field training resources to speed productivity gains, and the most recent new hire cohort is already outperforming prior cohorts at the same tenure stage. * The core U.S. hernia business continues to gain procedural market share, and LiquiFix delivered strong 39% YoY revenue growth; international business delivered consistent 26% YoY revenue growth across the UK and key European markets, and remains a durable growth driver for the company. * Management has upgraded talent in its market access and contracting team to counter anti-competitive bundling practices from large competitors, which remain a barrier to broader Ovitex adoption in U.S. hospital systems; the company's ongoing lawsuit against Becton Dickinson centers on these anti-competitive practices. - Financial Performance * Total Q2 2026 gross profit was $13.9 million, slightly below the $14.1 million YoY figure, while gross margin improved to 72% from 70% YoY, driven by tariff refunds and lower excess/obsolete inventory charges as a percentage of revenue. * Total operating expenses were flat YoY at $23.2 million: sales and marketing expense decreased by $400,000, R&D increased by $500,000 due to higher study and compensation costs, and G&A was flat YoY. * Operating loss was $9.3 million, up from $9.1 million YoY; net loss was $11.3 million, up from $9.9 million YoY, primarily due to higher interest expense from the company's upsized November 2025 credit facility. * End-of-quarter cash and cash equivalents totaled $30.4 million.
Guidance
- Management withdrew all prior full-year 2026 revenue guidance, as Q2 2026 results came in below expectations and new leadership is finalizing a cost restructuring plan to align operating costs with current top-line performance. * Management expects PRS revenue to recover in the second half of 2026, following the end of the failed pilot, rollout of new sales training, re-engagement with lapsed key surgeon users, and typical seasonal PRS strength in the back half of the year. * Management expects the overall business to grow in the second half of 2026 compared to the first half, supported by PRS recovery and continued expansion of the core hernia business focusing on higher-average-selling-price complex abdominal wall repairs. * The primary goal of the upcoming cost restructuring plan is to extend the company's cash runway as much as possible, with any additional fundraising expected to be a last resort. Updated full-year guidance will be provided after the restructuring plan is finalized.
Segment performance
1. Ovitex (core hernia portfolio): Total revenue of $13.3 million, up 6.6% year-over-year (YoY). Global Ovitex unit volume grew 12% YoY to 5,776 units, with unit growth outpacing dollar revenue growth due to an industry-wide shift toward smaller, lower-priced units driven by the rise of robotic hernia repairs. This segment accounts for approximately 68.9% of total Q2 2026 revenue. Ovitex international revenue grew 26% YoY to $3.8 million, all coming from the hernia portfolio, as Ovitex PRS is still in the European regulatory approval process. Revenue contribution from international business is ~19.7% of total revenue. 2. Ovitex PRS (plastic and reconstructive surgery): Revenue was $5.5 million, down 24.7% YoY from $7.3 million in Q2 2025, driven by a 23% decline in PRS unit volume. This segment accounts for approximately 28.5% of total Q2 2026 revenue. 3. Other revenue (includes LiquiFix): Total revenue of $0.5 million, up 39% YoY. LiquiFix delivered a second consecutive strong quarter of double-digit growth. This segment accounts for approximately 2.6% of total Q2 2026 revenue.
Risks & headwinds
- Anti-competitive bundling and contracting practices by large competitors continue to create significant barriers to Ovitex adoption in U.S. hospital systems, with competitors threatening hospitals with price increases for other products if they add TeleBio to their contract lineup, limiting the company's ability to compete on clinical outcomes even with a superior product. This dynamic has slowed sales rep productivity ramp over the past 18 months. * New sales representative productivity ramp is taking longer than the original 6-month target, delaying expected top-line growth from the company's investment in expanding the field sales team. * Ovitex PRS revenue is concentrated among a small cohort of high-volume implanting surgeons, making the segment vulnerable to revenue shocks from unexpected changes (such as career shifts or medical leave) among this small group. * The company reported a net loss of $11.3 million in Q2 2026 and ended the quarter with $30.4 million in cash; without cost cuts or additional fundraising, the company has limited runway to fund ongoing operations and product expansion. * Ovitex PRS has not yet completed regulatory approval for the European market, limiting international growth opportunity for the segment.
Analyst Q&A
Q: An analyst asked for an update on TeleBio's sales team, including current headcount pace and how much longer new representative ramp to productivity is taking compared to the prior 6-month target. /
A: Management confirmed hiring is on track with the original plan, and all headcount growth is from deliberate expansion rather than turnover. New reps now have an expected 9-12 month ramp to full productivity, with additional training resources added to help the new cohort reach target productivity by late 2026. The latest cohort of new hires is already outperforming prior groups at the same tenure stage.
Q: An analyst asked for clarification on PRS headwinds, specifically whether the failed pilot or surgeon concentration/lifestyle changes were the larger factor, and whether both headwinds will resolve in the second half of 2026. /
A: Management noted the main issues were the pilot causing sales focus confusion, plus unexpected absences and departures of top PRS surgeons that disproportionately impacted revenue due to the segment's concentrated user base. Both headwinds are being addressed: the pilot has been ended, and one top performing PRS sales rep who left in January has returned in July, with most absent surgeons already back to practicing. Management expects PRS growth to resume in the back half of the year.
Q: An analyst asked how TeleBio can compete against anti-competitive bundling given its product has far better clinical outcomes than competitors' offerings, outside of the existing lawsuit. /
A: Management is addressing bundling from both top-down and bottom-up. Bottom-up, the company is growing its peer-to-peer clinical network, sharing outcome data at major industry conferences, and winning over surgeons who have experienced poor recurrence outcomes with competitors' products. Top-down, the company has upgraded its market access and contracting team to build relationships with hospital administration and make the economic value case for Ovitex based on its lower recurrence rates.
Q: An analyst asked about TeleBio's cash position and funding plans after the announced cost restructuring. /
A: TeleBio ended Q2 2026 with $30.4 million in cash and cash equivalents. The primary goal of the upcoming cost restructuring is to extend the company's cash runway as much as possible, with additional fundraising planned only as a last resort. Management will release full details of the plan once it is finalized.
Q: An analyst asked about the shift to smaller hernia units for robotic procedures and whether new focus on larger complex repairs will offset that ASP headwind. /
A: The industry-wide shift to smaller robotic units remains ongoing, but TeleBio has launched new products tailored to the robotic hernia market and is prioritizing growth in large, complex abdominal wall repairs that carry higher ASPs. Management expects the gap between unit growth and revenue growth will narrow, with ASP degradation stabilizing moving into 2027.